Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice
The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2021-09-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839570909811179520 |
|---|---|
| author | I. V. Kolyadina |
| author_facet | I. V. Kolyadina |
| author_sort | I. V. Kolyadina |
| collection | DOAJ |
| description | The luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life expectancy of patients. This review presents the features of the mechanism of action of CDK4/6 inhibitors, the most significant and updated results of large, randomized trials with ribociclib (MONALEESA-2, MONALEESA-3, and MONALEESA-7) assessing the efficacy and safety of combined endocrine therapy with various endocrine partners in a population of premenopausal women and menopausal patients. The prospects for the use of CDK4/6 inhibitors for therapy patients with visceral crisis are shown. |
| format | Article |
| id | doaj-art-3c8a1a5d108f4d77bbb46b1b1d0652e9 |
| institution | Matheson Library |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2021-09-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-3c8a1a5d108f4d77bbb46b1b1d0652e92025-08-04T14:33:41ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272021-09-0117210.17650/1994-4098-2021-17-2-58-67687Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practiceI. V. Kolyadina0Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia; V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaThe luminal HER2-negative subtype is the dominant variant of metastatic breast cancer; modern combined endocrine therapy with CDK4/6 inhibitors due to significantly change the prognosis of the disease, not only for increasing progression free survival, but also for significantly prolonging the life expectancy of patients. This review presents the features of the mechanism of action of CDK4/6 inhibitors, the most significant and updated results of large, randomized trials with ribociclib (MONALEESA-2, MONALEESA-3, and MONALEESA-7) assessing the efficacy and safety of combined endocrine therapy with various endocrine partners in a population of premenopausal women and menopausal patients. The prospects for the use of CDK4/6 inhibitors for therapy patients with visceral crisis are shown.https://ojrs.abvpress.ru/ojrs/article/view/845combined endocrine therapyinhibitors cdk4/6ribociclibmonaleesa-2monaleesa-3monaleesa-7visceral crisis |
| spellingShingle | I. V. Kolyadina Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice Опухоли женской репродуктивной системы combined endocrine therapy inhibitors cdk4/6 ribociclib monaleesa-2 monaleesa-3 monaleesa-7 visceral crisis |
| title | Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice |
| title_full | Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice |
| title_fullStr | Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice |
| title_full_unstemmed | Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice |
| title_short | Ribociclib in the treatment of HR+ HER2-negative metastatic breast cancer: updated results from the randomized clinical trials and their role in the clinical practice |
| title_sort | ribociclib in the treatment of hr her2 negative metastatic breast cancer updated results from the randomized clinical trials and their role in the clinical practice |
| topic | combined endocrine therapy inhibitors cdk4/6 ribociclib monaleesa-2 monaleesa-3 monaleesa-7 visceral crisis |
| url | https://ojrs.abvpress.ru/ojrs/article/view/845 |
| work_keys_str_mv | AT ivkolyadina ribociclibinthetreatmentofhrher2negativemetastaticbreastcancerupdatedresultsfromtherandomizedclinicaltrialsandtheirroleintheclinicalpractice |